Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Fruquintinib × Irinotecan × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5 Stomach Neoplasms 3 Colonic Neoplasms 2 Uterine Cervical Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Liver Neoplasms 1 Gallbladder Neoplasms 1 Fruquintinib 1 Esophageal Neoplasms 1 Colorectal Cancer Metastatic 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Ampullary Adenocarcinoma 1

Interventions

Irinotecan 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06169202 2023-12-13

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients

China Medical University, China

Gastrointestinal

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡